This was demonstrated recently in a phase-1 clinical trial of adoptive transfer of expanded NK cells in combination with IgG1 antibody in patients with CRC and gastric cancer, in which this combinatory immunotherapy enhanced IFN-γ production and reduced peripheral Treg cells, and some patients showed an overall decrease in tumor size [112]. The gene discussed is IFNG; the disease is neoplasm.